Related Experiment Video
Updated: May 21, 2026
07:22
Basophil Activation Test for Allergy Diagnosis
Published on: May 31, 2021
Assessing basophil functional measures during monoclonal anti-IgE therapy
Sarbjit S Saini1, Donald W MacGlashan
1John Hopkin's University, School of Medicine, USA. ssaini@jhmi.edu
Journal of Immunological Methods
|June 6, 2012
Summary
Monitoring allergic disease involves assessing basophil responses to allergens. Omalizumab therapy, targeting IgE, can be monitored by measuring changes in basophil reactivity, aiding clinical management.
Area of Science:
- Immunology
- Allergy and Clinical Immunology
- Pharmacology
Background:
- Assessing therapeutic interventions in allergic diseases requires monitoring clinical and immunological responses.
- Basophil allergen reactivity is a validated measure reflecting clinical allergic disease expression.
- Omalizumab, a monoclonal antibody targeting IgE, is an established adjunct therapy for allergic conditions.
Purpose of the Study:
- To review methods for monitoring basophil allergen reactivity.
- To focus on the impact of omalizumab therapy on basophil responses.
- To discuss the implications for clinical disease management in allergic patients.
Main Methods:
- Review of existing literature on basophil function assays.
- Analysis of studies measuring basophil responses in the context of omalizumab treatment.
- Correlation of basophil reactivity changes with clinical outcomes.
Main Results:
- Basophil activation assays can quantify allergen-induced responses.
- Omalizumab therapy demonstrably alters basophil sensitivity to allergens.
- Changes in basophil reactivity correlate with therapeutic efficacy and disease control.
Conclusions:
- Monitoring basophil allergen reactivity provides insights into the immunologic effects of therapies like omalizumab.
- These measurements can inform and guide clinical management strategies for allergic diseases.
- Evaluating basophil responses offers a functional correlate of treatment response.
